Navigation Links
Allied Healthcare Products Reports First Quarter Loss on Sales Decline
Date:11/8/2011

ST. LOUIS, Nov. 8, 2011 /PRNewswire/ -- Allied Healthcare Products, Inc. (NASDAQ: AHPI) reported a loss in its first quarter on a decline in sales.

Allied's net loss for the first quarter of its 2012 fiscal year was approximately $145,000, or a negative 2 cents per basic and diluted share, versus a loss of about $88,000, or a negative 1 cent per share, in the previous year's first quarter.

Allied's sales for the quarter ending September 30, 2011 totaled about $11.4 million. This represents a decline of approximately 4 percent from the previous year's first quarter sales of about $11.9 million. Sales remain constrained by recession driven budget cuts in both hospitals and municipalities but the decline in sales between the two periods is believed by the Company to be a result of order timing rather than any further market declines.

The Company incurred expenses of about $400,000 in bringing production of Carbolime in-house during the first quarter. This production expense will be reduced by more than half in the second quarter and eliminated in the fiscal year's third and fourth quarters, resulting in improved margins.

Allied also reported significantly higher commodity prices in the quarter. Prices for commodities such as brass and resin increased by more than 20 percent over prior year levels. Prices for non-commodity goods increased by about 4 percent over the prior year.

Allied Healthcare Products manufactures a variety of respiratory products used in the healthcare industry in a range of hospital and alternate care settings including sub-acute facilities, home healthcare and emergency medical care. Allied's product lines include respiratory care products, medical gas equipment and emergency medical products. Allied's products are marketed to hospitals, hospital equipment dealers, hospital construction contractors, home healthcare dealers and e
'/>"/>

SOURCE Allied Healthcare Products, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Recession Continues to Depress Sales at Allied Healthcare Products
2. Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions
3. Allied Healthcare Announces Litholyme(TM) -- New CO2 Absorbent Used in Anesthesia
4. Recession Leads to Sales Decline and Loss for Allied Healthcare Products in Fiscal 2010
5. Allied Telesis, Hosted PACS Solutions Join Forces to Deliver Managed Cloud-Based Picture Archiving and Communications Systems (PACS) Services
6. Allied Healthcare Products Reports Narrow Loss for Quarter But Improves Year-Over-Year Performance
7. Allied Healthcare Products Reports Modest Profit for Quarter
8. Allied Healthcare Earns Modest Profit in Tight Market
9. Allied Healthcare Reports Profitable Quarter and Year Despite Lingering Effects of Recession
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014 Boston Scientific ... participate in the 2014 Credit Suisse Annual Healthcare Conference ... , AZ.  Dan Brennan , executive vice ... about the company beginning at approximately 8:00 a.m. PT ... A live webcast of the presentation and question and ...
(Date:10/30/2014)... 2014  Nektar Therapeutics (Nasdaq: NKTR ) ... ended September 30, 2014 on Thursday, November 6, 2014, ... Robin , president and chief executive officer, will host ... 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... audio-only Webcast of the conference call can be accessed ...
(Date:10/30/2014)...   Auxilium Pharmaceuticals , Inc. (NASDAQ: ... company, today announced financial results for the third ... important corporate, commercial, regulatory and clinical development updates ... very pleased with the continued momentum and strong ... portfolio this quarter, especially the XIAFLEX franchise, which ...
Breaking Medicine Technology:Boston Scientific To Participate In 2014 Credit Suisse Annual Healthcare Conference 2Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 3Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 4Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 5Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 6Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 7Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 8Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 9Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 10Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 11Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 12Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 13Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 14Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 15Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 16Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 17Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 18Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 19Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 20Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 21Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 22
... in Combination with CRESTOR (rosuvastatin calcium) Improved LDL, HDL ... ... SEATTLE, May 31 New Phase III data showed,that in ... AstraZeneca,s CRESTOR(R) (rosuvastatin,calcium) led to greater improvements than the corresponding ...
... Annual Meeting -, SOUTH SAN FRANCISCO, ... Pharmaceuticals, Inc. (Nasdaq: PARD ), a ... safety and,efficacy data from its ongoing Phase ... docetaxel and prednisone, the standard of care ...
Cached Medicine Technology:Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR(R) Meets Primary Endpoints on Key Lipids 2Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR(R) Meets Primary Endpoints on Key Lipids 3Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR(R) Meets Primary Endpoints on Key Lipids 4Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer 2Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer 3Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer 4
(Date:10/30/2014)... , A mathematical model developed by NIH grantees predicts ... to prevent HIV infection via vaginal sex, whereas just ... infection via anal sex. This finding helps explain why ... PrEP, in women failed to show efficacy. Participants in ... of Truvada and tenofovir (another antiretroviral) for HIV prevention ...
(Date:10/30/2014)... October 30, 2014 Graphics, coding, typography ... synonymous with the craft of web design and require ... Yet a simpler solution to create a website can ... videos, contact information, customer reviews and Facebook posts all ... "It is the next evolution of how a business ...
(Date:10/30/2014)... 30, 2014 Five months after their ... Street LLC announces new branding and a website to ... . After David Mepham’s promotion to name partner earlier ... website to include Mepham’s name and better reflect their ... mediation firm, the decision to implement new branding reflects ...
(Date:10/30/2014)... Radio listeners who indicate use of four ... of traditional radio commercials and have overwhelmingly endorsed custom ... a purchasing decision. , Those are some highlights from ... radio marketing company CRN International. The research is now ... respondents who indicated they have purchased or considered purchase ...
(Date:10/30/2014)... Thompson HealthDay Reporter WEDNESDAY, ... Liberia -- one of three West African nations ravaged by ... said Wednesday. Dr. Bruce Aylward, WHO,s assistant director general, ... in Liberia and no increase in laboratory-confirmed cases. He said ... the epidemic may be making some progress, The New ...
Breaking Medicine News(10 mins):Health News:Model by NIH grantees explains why HIV prevention dosing differs by sex 2Health News:Facebook Websites In Thirty-Seconds 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3
... , , WICHITA, Kan., ... public that late-term abortionist LeRoy Carhart will not be granted a transfer ... hours after Operation Rescue launched a pet i ... that Wesley Medical Center deny late-term abortionist LeRoy Carhart hospital or transfer ...
... RIVER EDGE, N.J., Aug. 14 Nephros, Inc. (OTC Bulletin Board: NEPH) announced today ... Recent Highlights , , , ... , Issued four new patents , ... , "2009 has continued to be a productive year for Nephros," said ...
... , , , , ... US: ADL), a U.S.-based pharmaceutical company with major operations in China, ... Rule 12b-25 of the Securities Exchange Act of 1934, as amended, ... Report on Form 10-Q for the second quarter ended June 30, ...
... , Visit by Lung Cancer ... , WASHINGTON, Aug. 14 /PRNewswire-USNewswire/ -- Today, Lung ... has signed on as a cosponsor of a bill to establish the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO ) , , ...
... effective with few side effects, study finds , FRIDAY, ... called Levadex is an effective treatment for migraines, according ... trial, conducted at the Jefferson Headache Center at Thomas ... who took the drug had greater relief from symptoms ...
... , WASHINGTON, Aug. 14 The Sixth ... of an Ohio law strictly regulating the provision of the dangerous ... CEO and President of Americans United for Life, stated, "This is ... providers have readily admitted that they administer RU-486 in violation of ...
Cached Medicine News:Health News:Operation Rescue: Wesley Medical Center Promises To Keep Carhart, Abortions Out 2Health News:Nephros Reports 2009 Second Quarter Financial Results 2Health News:Nephros Reports 2009 Second Quarter Financial Results 3Health News:Nephros Reports 2009 Second Quarter Financial Results 4Health News:Nephros Reports 2009 Second Quarter Financial Results 5Health News:AMDL Inc. Files Notification of Late Filing for Form 10-Q 2Health News:Senator Ben Nelson (D-NE) Joins as Co-Sponsor of Lung Cancer Mortality Reduction Act 2Health News:Senator Ben Nelson (D-NE) Joins as Co-Sponsor of Lung Cancer Mortality Reduction Act 3Health News:Americans United for Life Applauds Decision Protecting Women From Dangers of RU-486 2
...
It is a magnifying headlight perfect for all applications and procedures where clear magnification and a natural white light increase accuracy and productivity....
It is lightweight and portable headlight option for office exam room. It offers complete comfort and portability....
Solarc surgical headlight is durable, comfortable, lightweight and delivers the bright, white light expected from a xenon system, but at a fraction of the cost....
Medicine Products: